Skip to main content

Advertisement

SpringerLink
Log in

Biorecognition of HPMA Copolymer-Adriamycin Conjugates by Lymphocytes Mediated by Synthetic Receptor Binding Epitopes

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. The EDPGFFNVE nonapeptide (NP) was recognized as the CD21 (CR2) binding epitope of the Epstein-Barr virus (EBV) gp350/ 220 envelope glycoprotein which mediates the virus attachment to human B lymphocytes (Nemerow et al., Cell 56:369-377, 1989). Here we evaluated the targeting potential of a synthetic receptor binding epitope (NP) covalently attached to a water-soluble polymeric drug carrier. In particular, the biorecognition of N-(2-hydroxypropyl) metha-crylamide (HPMA) copolymer-NP conjugates by B- and T-cells and the cytotoxicity of HPMA copolymer-NP-adriamycin (ADR) conjugates toward B-cells, T-cells, and peripheral blood lymphocytes (PBL) were evaluated.

Methods. HPMA copolymer-NP and optionally ADR conjugates varying in the NP density and mode of NP attachment were incubated with Raji B-cells (human Burkitt's lymphoma), CCRF-CEM T-cells (acute human lymphoblastic leukemia), and CCRF-HSB-2 T-cells (human lymphoblastic leukemia). The kinetics of binding was studied, the Langmuir adsorption isotherms analyzed, binding constants calculated, and IC50 doses determined.

Results. Flow cytometry studies revealed that binding was homogeneous to both cell types. The apparent binding constants to T-cells were about two times higher when compared to B-cells. The binding and cytotoxicity increased with increased amount of epitopes per polymer chain. Attachment of the NP via a GFLG spacer resulted in increased biorecognition when compared with conjugates containing NP bound via a GG spacer. HPMA copolymer-NP-ADR conjugates possessed specific cytotoxicity to T- and B-malignant cells. Concentrations, which were lethal to the latter, were not toxic for PBL.

Conclusions. The data obtained seem to indicate the potential of the HPMA copolymer-NP conjugates as polymer anticancer drug carriers targetable to immunocompetent cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. D. Putnam and J. Kopeček. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:55–123 (1995).

    Google Scholar 

  2. H. Maeda, L. M. Seymour, and Y. Miyamoto. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:351–362 (1992).

    Google Scholar 

  3. R. Duncan, L. C. W. Seymour, L. Scarlett, J. B. Lloyd, P. Rejmanová, and J. Kopeček. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880:62–71 (1986).

    Google Scholar 

  4. B. Říhová, P. Kopečková, J. Strohalm, P. Rossmann, V. Větvička, and J. Kopeček. Antibody directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:100–114 (1988).

    Google Scholar 

  5. V. Omelyanenko, P. Kopečková, C. Gentry, J.-G. Shiah, and J. Kopeček. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the methods of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target. 3:357–373 (1996).

    Google Scholar 

  6. G. B. Sigal, M. Mammen, G. Dahman, and G. M. Whitesides. Polyacrylamides bearing pendant sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J. Am. Chem. Soc. 118:3789–3800 (1996).

    Google Scholar 

  7. R. C. Rathi, P. Kopečková, and J. Kopeček. Biorecognition of sugar containing N-(2-hydroxypropyl)methacrylamide copolymers by immobilized lectin. Macromol. Chem. Phys. 198:1165–1180 (1997).

    Google Scholar 

  8. A. V. Tersikh, J.-M. Le Doussal, R. Crameri, I. Fisch, J.-P. Mach, and A. V. Kajava, “Petabody”: A new type of high avidity binding protein. Proc. Natl. Acad. Sci. USA 94:1663–1668 (1997).

    Google Scholar 

  9. R. K. Jain, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:570–576 (1989).

    Google Scholar 

  10. N. L. Krinick, Y. Sun, D. Joyner, J. D. Spikes, R. C. Straight, and J. Kopeček. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomat. Sci., Polym. Ed. 5: 303–324 (1994).

    Google Scholar 

  11. J.-G. Shiah, Y. Sun, P. Kopečková, M. Peterson, and J. Kopeček. Biodistribution in tumor bearing mice of free and HPMA copolymer-bound meso-chlorin e6 and adriamycin. 25th Int. Symposium on Controlled Release of Bioactive Materials, Las Vegas, Nevada, June 21–24, 1998. Proceedings, pp. 95–96.

  12. S. K. Hobs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607–4612 (1998).

    Google Scholar 

  13. G. R. Nemerow, R. A. Houghten, M. D. Moore, and N. R. Cooper. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369–377 (1989).

    Google Scholar 

  14. D. Watry, J. A. Hedrick, S. Siervo, G. Rhodes, J. J. Lamberti, J. D. Lambris, and C. D. Tsoukas. Infection of human thymocytes by Epstein-Barr virus. J. Exp. Med. 173:971–980 (1991).

    Google Scholar 

  15. J. Kopeček and P. Rejmanová. Enzymatically degradable bonds in synthetic polymers. In S. D. Bruck (ed.), Controlled Drug Delivery, CRC Press, Boca Raton, Florida, 1983, vol. I, pp. 81–124.

    Google Scholar 

  16. P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka, and J. Kopeček. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:2009–2020 (1983).

    Google Scholar 

  17. J. Kopeček. Synthesis of tailor-made soluble polymeric carriers. In J. M. Anderson, S. W. Kim (eds.), Recent Advances in Drug Delivery Systems, Plenum Press, New York, NY, 1984, pp. 41–62.

    Google Scholar 

  18. M. B. Hansen, S. E. Nielsen, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growing/cell kill. J. Immunol. Meth. 119:203–210 (1989).

    Google Scholar 

  19. G. C. Salzman, J. M. Growell, J. C. Martin, et al. Cell identification by laser light scattering: Identification and separation of unstained leukocyte. Acta Cytol. (Praha) 19:374–377 (1975).

    Google Scholar 

  20. I. Vermes, C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using labeled Annexin V. J. Immun. Methods 184:39–51 (1995).

    Google Scholar 

  21. J. D. Lambris, V. S. Ganu, S. Hirani, and H. J. Muller-Eberhard. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc. Natl. Acad. Sci. U.S.A. 82:4235–4239 (1985).

    Google Scholar 

  22. J. Tanner, J. Weis, D. Fearon, Y. Whang, and E. Kieff. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203–213 (1987).

    Google Scholar 

  23. C. D. Tsoukas and J. D. Lambris. Expression of EBV/C3d receptors on T cells. Immunology Today 14:56–59 (1993).

    Google Scholar 

  24. E. Fischer, C. Delibrias, and M. D. Kazatchkine. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146:865–869 (1991).

    Google Scholar 

  25. G. Sauvageau, R. Stocco, S. Kasparian, and J. Menezes. Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes. J. Gen. Virol. 71:379–386 (1990).

    Google Scholar 

  26. R. Rask, J. M. Rasmussen, H. V. Hansen, P. Bysted, and S. E. Svehag. Complement C3dg/Epstein-Barr virus receptor density on human B lymphocytes estimated by immunoenzymatic assay and immunocytochemistry. J. Clin. Lab. Immunol. 25:153–156 (1988).

    Google Scholar 

  27. J. A. Hedrick, D. Watry, C. Speiser, P. O'Donnell, J. D. Lambris, and C. D. Tsoukas. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. Eur. J. Immunol. 22:1123–1131 (1992).

    Google Scholar 

  28. R. Stocco, G. Sauvageau, and J. Menezes. Differences in Epstein-Barr Virus (EBV) receptors expression on various human lymphoid targets and their significance to EBV-cell interactions. Virus Res. 11:209–225 (1988).

    Google Scholar 

  29. I. Muller, A. Jenner, G. Bruchelt, D. Niethammer, and B. Halliwell, Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 230:254–257 (1997).

    Google Scholar 

  30. R. K. Prakash, C. M. Clemens, C. D. Ebert, V. Omelyanenko, P. Kopečková, and J. Kopeček. Targeting of macromolecular prodrugs to T-lymphocytes. 24th Intern. Symp. Contr. Rel. Bioact. Mater., July 15–19, 1997 Stockholm, Sweden; Proceedings, pp. 859–860.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, 84112

    Vladimir Omelyanenko, Pavla Kopečková & Jindřich Kopeček

  2. TheraThech, Inc., Salt Lake City, Utah, 84108

    Ramesh K. Prakash & Charles D. Ebert

Authors
  1. Vladimir Omelyanenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pavla Kopečková
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramesh K. Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles D. Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jindřich Kopeček
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jindřich Kopeček.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Omelyanenko, V., Kopečková, P., Prakash, R.K. et al. Biorecognition of HPMA Copolymer-Adriamycin Conjugates by Lymphocytes Mediated by Synthetic Receptor Binding Epitopes. Pharm Res 16, 1010–1019 (1999). https://doi.org/10.1023/A:1018975414165

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018975414165

Search

Navigation